Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Cyborg Score Rationale
Recent momentum includes a new collaboration with Eli Lilly and strong 2025 product revenue figures. The company is progressing Phase 3 trials for IBI354, a HER2-directed antibody drug conjugate in breast cancer. However, valuation metrics show elevated P/E ratios relative to recent profitability.
Top Insights
Innovent surpassed RMB10 billion in 2025 product revenue on oncology and chronic disease momentum
Recent US$8.85 billion global oncology and immunology pact with Eli Lilly
Pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules
1-year total shareholder return of 131.43% reflecting strong recent momentum
Named Competitors
WuXi Biologics — Leading Chinese biotech and CDMO services provider
Roche/Genentech Oncology — Global oncology and immunology leader
Eli Lilly Oncology — Global pharma with oncology and metabolic disease focus
BeiGene — Chinese biotech with oncology focus
Recent Developments
(February 2026) Phase 3 HeriCare-Breast01 trial for IBI354 initiated
(February 2026) Strategic collaboration with Eli Lilly for oncology and immunology development
(February 2026) Surpassed RMB10 billion product revenue in 2025
Open the full interactive Innovent Biologics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.